Tonix Pharmaceuticals
 | This article, Tonix Pharmaceuticals, has recently been created via the Articles for creation process. Please check to see if the reviewer has accidentally left this template after accepting the draft and take appropriate action as necessary.
Reviewer tools: Inform author |
| This article, Tonix Pharmaceuticals, has recently been created via the Articles for creation process. Please check to see if the reviewer has accidentally left this template after accepting the draft and take appropriate action as necessary.
Reviewer tools: Inform author |
| This article, Tonix Pharmaceuticals, has recently been created via the Articles for creation process. Please check to see if the reviewer has accidentally left this template after accepting the draft and take appropriate action as necessary.
Reviewer tools: Inform author |
| This article, Tonix Pharmaceuticals, has recently been created via the Articles for creation process. Please check to see if the reviewer has accidentally left this template after accepting the draft and take appropriate action as necessary.
Reviewer tools: Inform author |
| This article, Tonix Pharmaceuticals, has recently been created via the Articles for creation process. Please check to see if the reviewer has accidentally left this template after accepting the draft and take appropriate action as necessary.
Reviewer tools: Inform author |
Comment: There's no automatic inherited notability from anything or anyone else, regardless and what's here is still not convincing our policies, none of it establishes actual substance. SwisterTwister talk 00:35, 2 January 2017 (UTC)
- Comment: Given that the product is only just now on the market, this may be too soon. In any case, remove the section called "news articles" although you can use information from those in the WP article and therefore cite them. As they are, their function is promotional and is not allowed. Do not use any articles that are only mentions of the company or short quotes from company officers. LaMona (talk) 15:32, 3 June 2016 (UTC)
- Comment: Remember to actually insert the references into the article, don't just list them at the end. Anarchyte (work | talk) 10:35, 12 May 2016 (UTC)
 | |
| Company type | Public |
|---|---|
| Nasdaq: TNXP | |
| Industry | Biotechnology Healthcare |
| Founded | United States (2007) |
| Headquarters | , United States |
Key people |
|
| Website | www |
Tonix Pharmaceuticals (Tonix Pharmaceuticals Holding Corp.) is a pharmaceutical company developing a pharmacological therapy for the treatment of posttraumatic stress disorder (PTSD), with initial development in patients with military-related PTSD.[1][2][3] Known as TNX-102 SL, this therapy is a formulation of cyclobenzaprine designed to be suitable for long-term use.[4][5] Based on data from a Phase 2 trial in military-related PTSD, TNX-102 SL was granted Breakthrough Therapy designation by the U.S. FDA on 19 December 2016 and had entered Phase 3 development as of 29 March 2017.[1][6][7] Tonix is also developing a smallpox vaccine based on synthesis of an ancestral virus strain that may have improved safety compared to existing stockpiled smallpox vaccines.[8][9][10][11][12][13]
History
Founded in 2007 and based in New York City, the company was listed on the NASDAQ exchange in 2013 under the symbol TNXP.[14]
References
- ^ a b Ellis, Lucie. “Just The Tonix: New York Biotech Has Breakthrough Drug for PTSD” Scrip, 22 December 2016. Retrieved 29 June 2017. (subscription required)
- ^ Baum, Stephanie. “Tonix Pharmaceuticals developing treatment for underserved PTSD patients” MedCity News, 23 June 2014. Retrieved 29 June 2017.
- ^ Keshavan, Meghana. [1] “Can a muscle relaxant ease symptoms of PTSD?”] STAT News, May 11, 2017. Retrieved 29 June 2017.
- ^ “Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride” U.S. Patent 96364078
- ^ [2] “Clinical News”] BioCentury, April 24, 2017. Retrieved on XX. (subscription required)
- ^ Fitzhugh, Michael. “Tonix Pharmaceuticals lands breakthrough status for PTSD drug” BioWorld, 20 December 2016. Retrieved on 29 June 2017. (subscription required)
- ^ “In the clinic” BioWorld, March 29, 2017. Retrieved 17 July 2017. (subscription required)
- ^ Hopper, Tristin. “Canadian synthesizes a better smallpox vaccine—just in case terrorists bring the disease back” National Post, March 2, 2017. Retrieved 29 June 2017.
- ^ Pong, Winnie, and Mark Zipkin. “1Q17 Public-Private Partnership Roundup” BioCentury, April 27, 2017. Retrieved 29 June 2017. (subscription required)
- ^ “Other news to note” BioWorld, March 3, 2017. Retrieved on 29 June 2017. (subscription required)
- ^ Kupferschmidt, Kai. "How Canadian researchers reconstituted an extinct poxvirus for $100,000 using mail-order DNA" Science, 6 July 2017. Retrieved 10 July 2017.
- ^ Achenbach, Joel and Lena H. Sun. [3] "Scientists synthesize smallpox cousin in ominous breakthrough"] The Washington Post, 7 July 2017. Retrieved 10 July 2017.
- ^ Branswell, Helen. "Scientists recreate an extinct virus, triggering new warnings about controversial research" STAT News, 7 July 2017. Retrieved 10 July 2017.
- ^ [4] "Tonix Pharmaceuticals Holding Corp. S-1/A" SEC. Retrieved 29 June 2017.
External links
- [5]www.tonixpharma.com
| This article, Tonix Pharmaceuticals, has recently been created via the Articles for creation process. Please check to see if the reviewer has accidentally left this template after accepting the draft and take appropriate action as necessary.
Reviewer tools: Inform author |